Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer

This is a non-comparative randomized Phase 2 study using the INITIUM regimen with or without elective nodal irradiation (ENI) delivered before surgery for resectable head and neck squamous cell carcinoma (HNSCC).

Trial Details

NCT ID
NCT07773987
Phase
PHASE2
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
Squamous Cell Head and Neck Cancer
Interventions
  • Pembrolizumab
  • Radiotherapy
  • ENI
  • Surgery
Locations (sample)
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Patients 18 years or older.
  • Patients with surgically resectable squamous cell carcinoma of the oral cavity or HPV-negative squamous cell carcinoma of the oropharynx. Resectabi…
  • A CPS score of at least 1 on initial biopsy.
  • Zubrod, or Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Head and Neck Cancer Trials on Trialify →